Ardelyx to Present at the Jefferies London Healthcare Conference
Ardelyx, Inc. (Nasdaq: ARDX) announced participation in a fireside chat at the Jefferies London Healthcare Conference from November 16-19, 2021. CEO Mike Raab will engage in discussions about the company's innovative medicines for kidney and cardiorenal diseases. The chat will be available on-demand for registered participants from 3:00 a.m. ET on November 18 to 12:00 p.m. ET on November 19, 2021. Ardelyx's product candidate tenapanor has completed three Phase 3 trials and is FDA-approved for IBS-C. The company has international agreements for tenapanor's development.
- None.
- None.
FREMONT, Calif. and WALTHAM, Mass., Nov. 11, 2021 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on the discovery, development, and commercialization of innovative first-in-class medicines to improve treatment for people with kidney and cardiorenal diseases, today announced that Mike Raab, president and chief executive officer of Ardelyx, will participate in a fireside chat at the Jefferies London Healthcare Conference, which is taking place virtually and in-person on November 16 – 19, 2021. The fireside chat will be available to all registered participants on-demand between 3:00 a.m. ET on November 18, 2021 and 12:00 p.m. ET on November 19, 2021.
To access the webcast of Ardelyx's presentation please visit the Events and Presentations page within the Ardelyx website at https://ir.ardelyx.com/events-and-presentations. A replay of the fireside chat will be available on the Ardelyx website for 30 days following the presentation.
About Ardelyx, Inc.
Ardelyx is focused on discovering, developing, and commercializing innovative first-in-class medicines to enhance the lives of patients with kidney and cardiorenal diseases. Ardelyx is developing tenapanor, a novel product candidate to control serum phosphorus in adult patients with CKD on dialysis, which has completed three successful Phase 3 trials. Ardelyx is also advancing RDX013, a potassium secretagogue, for the potential treatment of elevated serum potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease and has an early-stage program in metabolic acidosis, a serious electrolyte disorder in patients with CKD. In addition, tenapanor has already received FDA approval for the treatment of irritable bowel syndrome with constipation (IBS-C) under the tradename IBSRELA®. Ardelyx has established agreements with Kyowa Kirin in Japan, Fosun Pharma in China, and Knight Therapeutics in Canada for the development and commercialization of tenapanor in their respective territories.
View original content to download multimedia:https://www.prnewswire.com/news-releases/ardelyx-to-present-at-the-jefferies-london-healthcare-conference-301422612.html
SOURCE Ardelyx
FAQ
When will Ardelyx participate in the Jefferies London Healthcare Conference?
Who will represent Ardelyx at the Jefferies London Healthcare Conference?
What is the schedule for the Ardelyx fireside chat at the conference?
What products is Ardelyx developing?
Is tenapanor approved for any conditions?
